These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1268432)

  • 21. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 22. Compliance policy guide addresses prescription drug compounding.
    Ann Pharmacother; 1992 Jun; 26(6):868. PubMed ID: 1611176
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic response in oral dosage forms.
    Morrison AB
    Med Serv J Can; 1967 Mar; 23(3):349-59. PubMed ID: 6056377
    [No Abstract]   [Full Text] [Related]  

  • 24. Application of standards for compounding.
    Newton DW
    J Am Vet Med Assoc; 1994 Jul; 205(2):232-4. PubMed ID: 7928584
    [No Abstract]   [Full Text] [Related]  

  • 25. [Changes in the norms governing practices for the manufacture of pharmaceutical products: implications for the MERCOSUR].
    Temprano G; Prats S; Bregni C
    Boll Chim Farm; 1998 Nov; 137(10):426-38. PubMed ID: 9880947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons learned from good manufacturing practice noncompliance.
    Peskoe MP
    Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
    [No Abstract]   [Full Text] [Related]  

  • 27. Implementation of Current Good Manufacturing Practices in a small research laboratory setting.
    Keller CD; Taulbee SM
    Qual Assur; 1995 Mar; 4(1):83-6. PubMed ID: 8520870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Manufacturing and control in pharmaceutical industry. Introduction into manufacturing control. Introduction].
    Hippenmeier F
    Pharm Acta Helv; 1972; 47(11):625-8. PubMed ID: 4657531
    [No Abstract]   [Full Text] [Related]  

  • 29. [Round table on the "norms for good drug compounding"].
    Boll Chim Farm; 1970 Nov; 109(11):635-52. PubMed ID: 5515584
    [No Abstract]   [Full Text] [Related]  

  • 30. Comments on the ADD-vantage system.
    Robertson C; Schannuth R
    Am J Hosp Pharm; 1992 Jun; 49(6):1397. PubMed ID: 1529978
    [No Abstract]   [Full Text] [Related]  

  • 31. Comments on the ADD-Vantage system.
    Boylan JC
    Am J Hosp Pharm; 1992 Jun; 49(6):1396-7; author reply 1397-8. PubMed ID: 1529977
    [No Abstract]   [Full Text] [Related]  

  • 32. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug development history, "overview," and what are GCPs?
    Heilman RD
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 36. DEA revokes pharmacy's registration.
    J Am Vet Med Assoc; 2006 Jun; 228(11):1649-50. PubMed ID: 16752469
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 38. The Home Field Disadvantage.
    Cabaleiro J
    Int J Pharm Compd; 2016; 20(1):86-7. PubMed ID: 27125059
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
    Wigle WW
    Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
    [No Abstract]   [Full Text] [Related]  

  • 40. The Drug Quality and Security Act--mind the gaps.
    Outterson K
    N Engl J Med; 2014 Jan; 370(2):97-9. PubMed ID: 24369048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.